Without sugar, cancer cells die

Without sugar, cancer cells die

17/10/2013

More than half of all cancer cases show a significantly increased sugar metabolism. As a result, tumors continue to multiply unhindered, form metastases, and remain resistant to radiation and chemotherapy.

A recent study by the Berlin Charité - Universitätsmedizin and the Max Delbrück Center for Molecular Medicine proves again that cancer cells show an increased activity of the sugar metabolism. The scientists inhibited this sugar metabolism of the cells, they died. As early as 1924, the German biochemist and later Nobel laureate Otto Heinrich Warburg was able to detect an altered metabolism in carcinomas.

To maintain cell function and cell division, cells need sufficient energy. For this purpose, two different metabolic pathways for the production of energy - either combustion or fermentation - are available to a cancer cell. On „Switch“ The generation of energy from combustion to fermentation and the associated formation of lactic acid as a protective shield leads to the formation of resistance to radiation and chemo-therapy. Studies by the Institute of Physiology and Pathophysiology at Mainz University in 2011 showed that the intensity of lactic acid accumulation in cancer cells is closely related to the radiation and immune resistance of tumors, the formation of metastases and the overall survival of cancer patients.

TKTL1 metabolism is an additional way cells can convert glucose (blood sugar) into energy and has evolved as a protective mechanism in the course of evolution. Nerve cells remain longer, genetic information is stably relayed, and cells are protected from programmed cell death (apoptosis). Already 1995 discovered Dr. Johannes Coy the gene TKTL1 (transketolase-like-1), which carries every cell to switch to this metabolic pathway in itself. According to his findings, tumor cells are activated with the help of TKTL1 and initiate a protective mechanism via their modified sugar metabolism, which protects them from apoptosis and makes them resistant to chemotherapy and radiotherapy.

About one in two cancer patients have TKTL1-positive cells that are likely to prevent successful treatment and further promote cancer development. Therefore, in a cancer diagnosis by a blood test should first clarify whether TKTL1-positive cells, ie resistant cell structures are present.

Since this protective mechanism can not yet be remedied by medication, TAVARLIN AG has developed Coy Complete as a nutritional supplement to make tumor cells more sensitive to conventional cancer therapies. The patented formula corresponds to a ketogenic, ie low-carbohydrate diet, which should be used in TKTL1-positive findings to inhibit TKTL1 metabolism. It is a fully balanced, sugar-free drinking food that converts the body to a ketogenic metabolism, so that the energy source glucose is denied to tumor cells and they remain sensitive to the accompanying cancer therapy - without fasting. Additional nutrients, enriched with additional natural substances, additionally support. Patients with a diagnosed cancer and proven TKTL1 metabolism thus have the opportunity to positively influence the success of their surgery, radiation and chemotherapy on their own optimized diet. (Pm)